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ABSTRACT 
Background  
The outcome of patients with severe ischemic left ventricular (LV) dysfunction is 
determined by the extent of myocardial viability and the presence of LV 
dyssynchrony. We aimed at assessing both parameters from the same imaging 
method, i.e. gated positron emission tomography (PET) F18-fluorodeoxyglucose 
(FDG) scans.  
Methods  
Phase analysis from Emory Cardiac Toolbox was applied on gated PET-FDG scans 
to assess histogram bandwidth and standard deviation (SD) as a measure of LV 
dyssynchrony in 30 heart failure patients (mean ejection fraction: 30.2±13.8%) 
referred for the evaluation of myocardial viability. Cut-off values from single-photon 
emission computed tomography myocardial perfusion imaging (SPECT-MPI) best 
predicting cardiac resynchronization therapy (CRT) response served as standard of 
reference (bandwidth<135°; phase SD<43°). Severe LV dyssynchrony was 
diagnosed if both SPECT-MPI values were above these limits. Intraclass correlation 
and clinical agreement in detection of severe LV dyssynchrony by PET versus 
SPECT were assessed.  
Results  
There was a significant correlation between PET-FDG and SPECT-MPI for 
bandwidth (r=0.88, p<0.001) and phase SD (r=0.88, p<0.001) resulting in an 
excellent clinical agreement between the two methods of 93%. 
Conclusions 
Accurate LV dyssynchrony assessment by phase analysis of gated PET-FDG scans 
is feasible, allowing to assess myocardial viability and severe LV dyssynchrony in 
one scan. 
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INTRODUCTION 
Coronary artery disease (CAD) is one of the leading causes of morbidity and 
mortality in western countries. Patients with extensive coronary artery disease (CAD) 
are at higher risk to develop heart failure and left ventricular (LV) dysfunction. 
In patients with severe ischemic LV dysfunction revascularization of viable segments 
guided by myocardial PET-FDG findings has been shown to improve outcome.1, 2, 3, 4 
Recently, it has been shown that not only myocardial viability but also severe LV 
dyssynchrony is an independent predictor of perioperative outcome.5, 6 Therefore, it 
has been advocated that the assessment of myocardial viability and LV 
dyssynchrony should be a routine part of the preoperative evaluation of these 
patients.5   
Moreover, studies showed that the presence of LV dyssynchrony as well as the 
extent of scar tissue and viable myocardium is directly related to the response to 
cardiac resynchronization therapy (CRT). Therefore, it has been stated, that the 
evaluation for viability and LV dyssynchrony should be considered in the selection 
process for CRT.7, 8, 9, 10 
For the accurate assessment of LV dyssynchrony, different imaging methods, such 
as tissue Doppler imaging, multigated blood pool ventriculography acquisition 
(MUGA) and magnetic resonance imaging (MRI) have been developed. For long time, 
MUGA has been seen as the most accurate and reproducible non-invasive 
technique.11 Lately, phase analysis based on Fourier harmonic function on gated 
single-photon-emission computed tomography myocardial perfusion imaging 
(SPECT-MPI) has been suggested as a suitable option for LV dyssynchrony 
assessment.12, 13 
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As PET-FDG is considered the most specific tool for evaluation of viable tissue in 
ischemic LV dysfunction where LV dyssynchrony has emerged as independent 
predictor of outcome, the assessment of the latter by gated PET-FDG appears 
pertinent. Thus, the aim of this study was to validate the assessment of LV 
dyssynchrony from phase analysis from gated PET-FDG scans versus previously 
established phase analysis from gated SPECT-MPI as standard of reference.12, 13 
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MATERIALS AND METHODS 
The present study includes 30 consecutive patients with known CAD who were 
referred for evaluation of viable myocardium by SPECT MPI/PET-FDG because of 
severe ischemic LV dysfunction. Patients were included if they had signed informed 
consent authorizing their records to be included in our research registry. 
. 
SPECT-MPI image acquisition and interpretation 
The SPECT-MPI acquisition was performed approximately 1 hour after injection of 
750 MBq 99mTc-tetrofosmin at rest on a Ventri dual-head camera (Ventri, GE 
Healthcare) with a low-energy, high-resolution collimator, a 20% symmetric window 
at 140keV, a 64x64 matrix, and an elliptic orbit with step-and-shoot acquisition at 3° 
intervals over 180° arc (45° right anterior oblique to 45° left posterior oblique) with 30 
steps (60 views). Scan time was set to 25 seconds per frame for stress and rest, 
resulting in a total acquisition time of 14 minutes 52 seconds (including inter-step 
rotation time) for each scan as recommended by the American Society of Nuclear 
Cardiology (ASNC).14 Images were reconstructed on a dedicated workstation using a 
standard iterative reconstruction algorithm with Ordered Subset Expectation 
Maximization (OSEM) with 2 iterations and 10 subsets. Standard short as well as 
vertical, and horizontal long axis, and polar maps of perfusion encompassing the 
entire left ventricle were analysed using QGS/QPS software. Effective radiation dose 
for the SPECT-MPI study was calculated as 99mTc-tetrofosmin activity times 7.9 
mSv/GBq. 
 
PET-FDG image acquisition and interpretation 
Myocardial viability scans were acquired on a PET/CT scanner using 250 MBq of 
FDG. All patients were advised to fast for at least 6 hours before PET examination 
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and received a standardized oral glucose load.15 After FDG injection, patients rested 
for 1 hour before image acquisition. Images were acquired on a Discovery (LS/RX) 
PET/CT scanner (GE Healthcare). CT attenuation maps were used for AC as 
previously reported.16 Acquired images were reconstructed using attenuation 
weighted-OSEM iterative reconstruction (2 iterations and 8 subsets). FDG uptake 
polar maps were equally derived by using the Cedars QPS/QGS software package 
as for SPECT-MPI. Effective radiation dose for PET-FDG study was calculated as 
FDG activity times 0.019 mSv/MBq.  
 
Assessment of LV dyssynchrony by SPECT-MPI and PET-FDG 
The Emory Cardiac Toolbox software (Emory University/ Syntermed, Atlanta, Ga) for 
phase analysis and assessment of LV dyssynchrony from SPECT-MPI has been 
extensively validated.12, 13, 17 The software was applied on both, gated PET-FDG and 
SPECT-MPI scans to assess phase histogram bandwidth and standard deviation 
(SD), which are the two parameters best allowing determination of presence vs. 
absence of LV dyssynchrony. The previously established optimal cut-off value for the 
prediction of response to CRT, i.e. 135° for histogram bandwidth and 43° for phase 
SD,17 where used in the present study. Severe LV dyssynchrony was considered to 
be present if both of the parameters were above the cut off value. All images were 
analyzed by a reader who was blinded to the history of the patient.   
 
Statistical analysis 
All statistical analysis were performed using SPSS software (SPSS 15.0, Chicago, 
ILL, USA). Quantitative variables were expressed as mean ± standard deviation, and 
categorical variables were expressed as frequencies and percentages. Means of 
histogram bandwidth and phase SD assessed by the two different imaging methods 
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PET-FDG vs. SPECT-MPI were compared using Wilcoxon signed-rank test. 
Intraclass correlation of the two parameters histogram bandwidth and phase SD from 
PET-FDG vs. SPECT-MPI was performed. In addition, clinical agreement and Bland-
Altman (BA) limits of agreement were calculated. A p-value of <0.05 was considered 
to indicate statistical significance. 
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RESULTS 
In all 30 patients phase analysis of Emory Cardiac Toolbox was applied successfully 
using rest MPI scans and PET-FDG scans, respectively. Baseline characteristics of 
the entire study population are given in the table. The SPECT and FDG exams were 
performed in a time range between December 2007 and January 2010. The mean 
injected activity was 925 ± 12 MBq for the rest 99mTc-Tetrofosmin SPECT-MPI study 
and 252 ± 20 MBq for the PET-FDG study resulting in a total radiation dose of 7.3 ± 
1.0 mSv for the SPECT-MPI scan and 4.8 ± 0.4 mSv for the FDG exam, respectively.  
SPECT-MPI revealed a perfusion defect in 27 patients. Of these, 19 patients had at 
least partially preserved FDG uptake, indicating dysfunctional but viable tissue.  
Mean histogram bandwidth by SPECT-MPI and PET-FDG was 168.7° ± 78.4° and 
168.0° ± 66.7° (p=n.s.), respectively. Mean phase SD by SPECT-MPI and PET-FDG 
was 52.7° ± 23.2° and 57.3° ± 27.0° (p=n.s.). 
SPECT-MPI identified severe LV dyssynchrony in 18 patients with a mean histogram 
bandwidth of 225.2° ± 36.7° and a mean phase SD of 68.7° ± 11.3°. Normal LV 
synchronicity or mild LV dyssynchrony was found in 12 patients with a mean 
bandwidth of 83.9° ± 32.8° and a phase SD of 28.7° ± 13.1°. In 13 of these 18 
patients there was a flow-metabolism mismatch, i.e. a perfusion defect in SPECT but 
preserved FDG uptake in PET in at least one segment. PET-FDG scans revealed 
severe LV dyssynchrony in 20 patients among which the 18 patients identified by 
SPECT-MPI. Mean histogram bandwidth was 204.9°± 44.1° and mean phase SD 
was 68.7° ± 17.0°. Mean values of normal or mild findings by PET-FDG were 94.2° ± 
34.0° and 34.5° ± 15.1° for histogram bandwidth and SD, respectively. An example of 
dyssynchrony assessment from SPECT-MPI versus PET-FDG is illustrated in Figure 
1.  
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There was a significant correlation between SPECT-MPI data and PET-FDG scans 
for histogram bandwidth (r=0.88, p<0.001) and phase SD (r=0.88, p<0.001) (Figure 
2). Sensitivity, specificity, PPV and NPV on a per-patient base were 100%, 83%, 
90% and 100% for data sets from PET-FDG compared to SPECT-MPI as standard of 
reference. This resulted in an agreement of the two methods of 93%. 
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Discussion 
The present study investigates the use of FDG PET scans to assess severe LV 
dyssynchrony in patients with ischemic LV dysfunction referred for preoperative 
evaluation prior to CABG surgery. Our results reveal that LV dyssynchrony 
assessment from PET-FDG scans is feasible and accurate. This allows using the 
same scans performed for viability assessment also for assessment of LV 
dyssynchrony, which has recently shown to be an independent predictor of 
perioperative outcome in CABG surgery of patients with severe ischemic LV 
dysfunction.  
There are several therapeutic strategies, which have been considered for the 
treatment of patients with ischemic heart failure. As the value of medical therapy 
remains questionable,3, 18 other modalities such as coronary revascularization and 
resynchronization have gained importance as valuable treatment option in these 
patients. CABG surgery improves survival in patients with chronic CAD, and the 
presence of viability has been considered as one of the most important parameters of 
preoperative evaluation. Recently, a poor outcome in patients undergoing CABG 
surgery has been associated with the presence of severe LV dyssynchrony.5, 6 
Therefore, it has been suggested that both, viability as well as LV dyssynchrony 
should be routinely assessed before CABG surgery.5  
CRT is an established therapy for patients with advanced heart failure. The technique 
improves heart failure symptoms, exercise capacity, and LV function, with a reduction 
in morbidity and mortality.19, 20 However, 20-30% of all patients receiving a CRT do 
not respond. The search of reasons for nonresponse to CRT has gained importance 
in recent investigations. The presence of LV dyssynchrony as well as the extent of 
scar tissue and viable myocardium have been identified as key parameters directly 
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related to the response to CRT 7, 8, 9, 10 suggesting that the evaluation of patient 
selection for CRT should include these parameters.  
PET-FDG is the only method for viability assessment which has been shown to 
improve the outcome of patients when it is used to assist management of severe LV 
dysfunction.1 A broad diversity of imaging techniques has been established for LV 
dyssynchrony assessment, such as echocardiography, especially with tissue Doppler 
imaging (TDI) and strain imaging,21, 22 magnetic resonance imaging (MRI) and MUGA 
radionuclide ventriculography. TDI has emerged as one of the most widely used 
techniques but may be subject to interobserver variability in part related to observer 
experience.23 MUGA radionuclide ventriculography has overcome both of the above 
mentioned possible disadvantages but has not been widely used lately. Recently, 
assessment of LV dyssynchrony by phase analysis of gated SPECT-MPI scans has 
been established.12 The evaluation with gated SPECT-MPI scans has potential 
benefits, such as the automated and reproducible assessment and moreover the 
possibility to gather information on myocardial perfusion at the same time. The 
present study now shows that PET-FDG, which is used to assess viability, allows 
assessment of the two key parameters of severe LV dysfunction simultaneously. This 
enables comprehensive evaluation of patients before CABG surgery.    
 
We acknowledge following limitations: First, this is a single-center study with only a 
limited population of 30 patients due to the pilot nature of this study. Second, the use 
of manual base and apex placement may lead to bias, especially in a population 
which typically has a high prevalence of perfusion defects. However, it has been 
described earlier that repeatability of phase analysis is higher when using manual 
placement compared to the automated technique 24 justifying the manual placement 
tool for phase analysis. In addition, in patients with large fixed defects, the 
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assessment of LV dyssynchrony by phase analysis from SPECT-MPI may be 
hampered, due to limitations in contour detection. By contrast, many of these 
segments had preserved FDG uptake potentially allowing better contour detection by 
PET-FDG scanning. This may have accounted for the fact that in the upper range of 
LV dyssynchrony there appears to be larger variability between the two methods (see 
Figure 2).  
In conclusion, LV dyssynchrony assessment from PET-FDG scans is feasible and 
accurate, compared to the standard of reference SPECT-MPI, although our data may 
not support the interchangeable use of the two methods in patients with large 
perfusion defects.  
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Figure legends 
 
Figure 1 
Phase analysis of gated SPECT-MPI (A)  and PET-FDG (B) in a patient with severe 
LV dyssynchrony reveals comparable results for histogram bandwidth (281° and 
280°) and phase SD (79° and 81°), respectively.  
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Figure 2 
Correlation of histogram bandwidth (left) and phase SD (right) values between PET-
FDG versus SPECT-MPI (upper panel) and accuracy of PET-FDG to predict LV 
dyssynchrony (lower panel). Values greater than 43° (for phase SD) and 135° (for 
histogram bandwidth) from SPECT-MPI were considered abnormal (according to ref. 
17) 
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TABLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table. Baseline characteristics of study population (n=30) 
  
Male 22 (73.3%) 
Age (y)  
mean ± SD, (range) 64 ± 14, (35 - 83) 
Body mass index (kg/m2)  
mean ± SD, (range) 25.8 ± 3.7, (20.7 - 34.9) 
Ejection fraction (%)  
mean ± SD, (range) 30.2 ± 13.8, (11 - 55)  
Hypertension  17 (57%) 
Dyslipidemia 10 (33%) 
Diabetes 8 (27%) 
Smoking 16 (53%) 
Positive Family History 6 (20%) 
